Liraglutide in Children and Adolescents with Type 2 Diabetes.
William V TamborlaneMargarita Barrientos-PérezUdi FainbergHelle Frimer-LarsenMona HafezPaula M HaleMuhammad Y JalaludinMargarita KovarenkoIngrid LibmanJane L LynchPaturi RaoNaim ShehadehSerap TuranDaniel WeghuberTimothy Barrettnull nullPublished in: The New England journal of medicine (2019)
In children and adolescents with type 2 diabetes, liraglutide, at a dose of up to 1.8 mg per day (added to metformin, with or without basal insulin), was efficacious in improving glycemic control over 52 weeks. This efficacy came at the cost of an increased frequency of gastrointestinal adverse events. (Funded by Novo Nordisk; Ellipse ClinicalTrials.gov number, NCT01541215.).